ASCO 2019
ASCO 2019 Videos
Elderly Patients With Breast Cancer and CVD Risk Factors Found More Likely to Visit ER
Neratinib Improved PFS Compared With Lapatinib
EGFR-Mutant mNSCLC: Outcomes of Gefitinib + Pemetrexed-Carboplatin Chemotherapy
Pazopanib Found Not Beneficial Following Metastasectomy
Adjuvant Whole-Brain Radiotherapy Not Recommended for Melanoma Brain Metastases
Neoadjuvant Therapy Tied to High Pathological Response Rates
Heparin Derivative CX-01 May Boost Standard AML Induction
Sequential Exposure to FOLFOXIRI Plus Bevacizumab Shows Benefit
Promising Early Results for Preoperative Atezolizumab
ASCT Reduced the Risk of Early Relapse for Some Patients
BRAF and MEK Inhibitors Deemed Superior to Anti–PD-1
Novel Metric Sheds Light on When Adverse Events May Occur
Results of Enfortumab Vedotin Monotherapy for Urothelial Cancer
Randomized Phase III Trial of Lenalidomide vs. Observation Alone
Association of PBAF Complex Mutations With Survival
Gilteritinib Superior to Salvage Chemo
Adjuvant Ipilimumab Determined to Increase Overall Survival
Update at 9 Years of the GETUG-AFU 16 Phase III Randomized Trial
Pembrolizumab Improves Survival in NSCLC
ASCO 2019 Complete Coverage
Prospective Evidence Links Textured Breast Implants to Rare Lymphoma
The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
Breastfeeding Duration May Influence Markers of Inflammation and Proliferation in Breast Tissue of Healthy Parous Women
Morphologic features were examined to identify markers of inflammation, and proliferation index was assessed using Ki67 immunostaining.
Efficacy of Maintenance Therapy After Induction Therapy in Patients With Nonsquamous NSCLC and Wild-Type EGFR
In this patient subset, BEV+PEM maintenance therapy after CAR+PEM+BEV induction therapy “could have survival benefits.”
EGFR-Mutant mNSCLC: Outcomes of Gefitinib + Pemetrexed-Carboplatin Chemotherapy Versus Gefitinib Alone
Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but also increased toxicity.
RELAY Phase 3: Efficacy of the Addition of Ramucirumab to Erlotinib in EGFR-Mutant Metastatic NSCLC
RELAY is a multicenter, double-blind, randomized clinical trial that enrolledin patients who had no prior treatment for 1L epidermal growth factor receptor (EGFR)-mutant metastatic non−small cell lung cancer.
Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCC
The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.
Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Early MRD Status After CAR-T Administration Predicted PFS, OS
An analysis of patients in the ZUMA-1 trial found that day 28 minimal residual disease levels could identify patients at risk for early progression.
Adding Apalutamide to ADT Prolongs Survival in mCSPC
In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.
Earlier Pembrolizumab Use May Be Beneficial in mUC
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
PET/CT Imaging for Recurrent PCa Detection More Accurate With PSMA
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
More Advanced PCa Diagnoses Followed USPSTF Screening Recommendations
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
Nonrelapse Mortality After CAR-T Therapy Remains High
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
Early Study of PI3K Inhibitor Yields High Response Rate in R/R Follicular Lymphoma
Additional research is needed on the best dose schedule for the drug.
Value Frameworks Back Checkpoint Inhibitor Approvals in Palliative Setting
Frameworks used to make prescribing decisions on checkpoint inhibitors may need to be refined for adjuvant trials.
Adjuvant Whole-Brain Radiotherapy Not Recommended for Melanoma Brain Metastases
Secondary end points were not significantly different between the 2 groups, including overall survival.
How to Treat Melanoma After Checkpoint Inhibitors Fail
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Adjuvant Ipilimumab Determined to Increase Overall Survival in High-Risk Melanoma
Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.
Neoadjuvant Therapy in Melanoma Tied to High Pathological Response Rates
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
Venetoclax Plus Obinutuzumab Prevails as First-Line Combo in CLL
Patients with chronic lymphocytic leukemia who received venetoclax plus obinutuzumab had better survival outcomes compared with chemoimmunotherapy.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...